You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

FEBUXOSTAT - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for febuxostat and what is the scope of patent protection?

Febuxostat is the generic ingredient in two branded drugs marketed by Alembic, Alkem Labs Ltd, Aurobindo Pharma Ltd, Dr Reddys, Hikma, Indoco, Lupin Ltd, Macleods Pharms Ltd, MSN, Mylan, Prinston Inc, Sun Pharm, Sunshine, Torrent, Zydus Lifesciences, and Takeda Pharms Usa, and is included in sixteen NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Febuxostat has twenty-eight patent family members in fifteen countries.

There are twenty-six drug master file entries for febuxostat. Twenty-three suppliers are listed for this compound. There is one tentative approval for this compound.

Drug Prices for FEBUXOSTAT

See drug prices for FEBUXOSTAT

Recent Clinical Trials for FEBUXOSTAT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Jiangsu HengRui Medicine Co., Ltd.Phase 3
JW PharmaceuticalPhase 3
Chinese University of Hong KongPhase 2

See all FEBUXOSTAT clinical trials

Generic filers with tentative approvals for FEBUXOSTAT
Applicant Application No. Strength Dosage Form
⤷  Sign Up⤷  Sign Up40MGTABLET;ORAL
⤷  Sign Up⤷  Sign Up80MGTABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for FEBUXOSTAT
Medical Subject Heading (MeSH) Categories for FEBUXOSTAT
Paragraph IV (Patent) Challenges for FEBUXOSTAT
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ULORIC Tablets febuxostat 40 mg and 80 mg 021856 10 2013-02-13

US Patents and Regulatory Information for FEBUXOSTAT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm FEBUXOSTAT febuxostat TABLET;ORAL 205467-002 Jul 1, 2019 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lupin Ltd FEBUXOSTAT febuxostat TABLET;ORAL 205406-001 Jan 17, 2024 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lupin Ltd FEBUXOSTAT febuxostat TABLET;ORAL 205406-002 Jan 17, 2024 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Dr Reddys FEBUXOSTAT febuxostat TABLET;ORAL 205374-001 Oct 22, 2020 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-002 Feb 13, 2009 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Msn FEBUXOSTAT febuxostat TABLET;ORAL 210461-001 Dec 30, 2019 BX RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for FEBUXOSTAT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-002 Feb 13, 2009 ⤷  Sign Up ⤷  Sign Up
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-002 Feb 13, 2009 ⤷  Sign Up ⤷  Sign Up
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-001 Feb 13, 2009 ⤷  Sign Up ⤷  Sign Up
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-001 Feb 13, 2009 ⤷  Sign Up ⤷  Sign Up
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-002 Feb 13, 2009 ⤷  Sign Up ⤷  Sign Up
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-001 Feb 13, 2009 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for FEBUXOSTAT

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Krka, d.d., Novo mesto Febuxostat Krka febuxostat EMEA/H/C/004773
Febuxostat Krka is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).Febuxostat Krka is indicated in adults.
Authorised yes no no 2019-03-28
Mylan Pharmaceuticals Limited Febuxostat Mylan febuxostat EMEA/H/C/004374
Febuxostat Mylan is indicated for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS).Febuxostat Mylan is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).Febuxostat Mylan is indicated in adults.
Authorised yes no no 2017-06-15
Menarini International Operations Luxembourg S.A. (MIOL) Adenuric febuxostat EMEA/H/C/000777
80 mg strength:Treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).Adenuric is indicated in adults.120 mg strength:Adenuric is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).Adenuric is indicated for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS).Adenuric is indicated in adults.
Authorised no no no 2008-04-21
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for FEBUXOSTAT

Country Patent Number Title Estimated Expiration
Russian Federation 2013109380 СПОСОБ СОПУТСТВУЮЩЕЙ ТЕРАПИИ С ПРИМЕНЕНИЕМ ТЕОФИЛЛИНА И ФЕБУКСОСТАТА ⤷  Sign Up
Spain 2505690 ⤷  Sign Up
Japan 4084309 ⤷  Sign Up
China 1642546 Solid preparation containing single crystal form ⤷  Sign Up
South Korea 20130097775 METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTAT ⤷  Sign Up
South Korea 20040101284 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for FEBUXOSTAT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1020454 PA 2010 005, C 1020454 Lithuania ⤷  Sign Up PRODUCT NAME: FEBUXOSTATUM; REGISTRATION NO/DATE: EU/1/08/447/001-EU/1/08/447/004 20080421
1020454 PA2010005 Lithuania ⤷  Sign Up PRODUCT NAME: FEBUXOSTATUM; REGISTRATION NO/DATE: EU/1/08/447/001-EU/1/08/447/004 20080421
1020454 19/2010 Austria ⤷  Sign Up PRODUCT NAME: FEBUXOSTAT IN DER KRISTALLFORM A; REGISTRATION NO/DATE: EU/1/08/447/001-004 20080421
1020454 SPC/GB10/019 United Kingdom ⤷  Sign Up SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB10/019 GRANTED TO TEIJIN LIMITED IN RESPECT OF THE PRODUCT FEBUXOSTAT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6408 DATED 14/03/2012 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22/04/2023.
1488790 C20140037 00152 Estonia ⤷  Sign Up PRODUCT NAME: FEBUKSOSTAAT;REG NO/DATE: EU/1/08/447 23.04.2008
1020454 PA2010005,C1020454 Lithuania ⤷  Sign Up PRODUCT NAME: FEBUXOSTATUM; REGISTRATION NO/DATE: EU/1/08/447/001-EU/1/08/447/004, 0080421
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.